Renaissance Technologies LLC Acquires 31,435 Shares of Phibro Animal Health Corporation $PAHC

Key Points

• Renaissance Technologies increased its Phibro Animal Health stake by 5.8%, purchasing 31,435 additional shares to own 576,735 shares, or approximately 1.42% of the company.
• Analyst sentiment has weakened, with several firms downgrading the stock and Citigroup cutting its price target to $44. The consensus rating is now “Hold”, with a $42.50 price target.
• Phibro exceeded quarterly earnings and revenue expectations, reporting $0.76 EPS and $383.54 million in revenue, while declaring a quarterly dividend of $0.12 per share, representing a 1.3% yield.

Renaissance Technologies LLC raised its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 576,735 shares of the company's stock after buying an additional 31,435 shares during the period. Renaissance Technologies LLC owned about 1.42% of Phibro Animal Health worth $31,899,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. KBC Group NV purchased a new position in shares of Phibro Animal Health in the first quarter worth about $29,000. 1620 Investment Advisors Inc. boosted its holdings in Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company's stock valued at $25,000 after acquiring an additional 295 shares during the period. Farther Finance Advisors LLC grew its position in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock worth $27,000 after acquiring an additional 386 shares during the last quarter. Rothschild Investment LLC grew its position in Phibro Animal Health by 2,500.0% during the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company's stock worth $39,000 after acquiring an additional 1,000 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in Phibro Animal Health during the 3rd quarter worth approximately $61,000. 99.34% of the stock is owned by institutional investors.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the firm's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the sale, the chief executive officer directly owned 67,720 shares in the company, valued at $3,778,776. This trade represents a 9.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,608 shares of company stock valued at $983,825 over the last ninety days. 50.13% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have weighed in on PAHC. Wall Street Zen downgraded Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. Weiss Ratings cut shares of Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, June 15th. Citigroup decreased their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating on the stock in a research note on Thursday, May 14th. Finally, Zacks Research lowered shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 21st. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $42.50.

Phibro Animal Health Stock Performance

Shares of PAHC stock opened at $36.37 on Wednesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 0.49 and a beta of 0.46. The stock has a fifty day moving average of $32.52 and a 200 day moving average of $43.24. Phibro Animal Health Corporation has a 52 week low of $25.58 and a 52 week high of $60.08. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts expect that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health's payout ratio is currently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.